中国干细胞、癌症免疫疗法第一股崩盘

tim1403

; E9 `+ I9 m: r4 a. @6 h: |

" U& N" N: p/ G9 b- K( X中国干细胞、癌症免疫疗法第一股崩盘
$ m; h3 e- q) ?" ?2 U" O2015-06-26
5 J+ m& f8 Q# g$ }7 K 1 Q1 f# a+ f- J$ c5 @
Here's still a biotech investment lesson: be careful of Chinese fraudsters in biotech clothing.
0 t: H, m( ^& u. N6 R  j
8 t5 |5 V1 z6 Z7 l/ L9 L1 t# b3 h: [1 {/ f2 R
On April 7, 2015, The Pump Stopper at Seeking Alpha released a bearish report claiming that Cellular Biomedicine (NASDAQ: CBMG) has achieved an unsustainable valuation with paid stock promotion. The company’s cell therapies are worthless and certain executives have questionable histories.
4 E7 A+ L; Z4 S& Z! h
  a9 ~7 n  ~: W% [
; Z' [# s! {: fCellular Biomedicine is a Chinese cell therapy stock which I stumbled upon when LifeTech Capital released an extremely bullish report with a target price of $32.50. I felt very strange, but I didn’t find any solid evidence against LifeTech Capital. Now it turned out to be a paid stock promotion.
$ k4 j! d. ]4 {& n. p8 Z: h0 V" Y: Z6 d4 \

9 d1 }& Y( S8 H3 _In February 2015, Cellular Biomedicine acquired CAR-T therapies targeting CD19, CD20, CD30, and EGFR from the Chinese PLA General Hospital in a RMB12 million deal. It sounds too cheap to be true. Furthermore, the company’ R&D expense was much lower than G&A cost in the last two years (2014: $2.67 vs. $8.41 million; 2013: $1.89 vs. $9.31 million)., and EGFR from the Chinese PLA General Hospital in a RMB12 million deal. It sounds too cheap to be true. Furthermore, the company’ R&D expense was much lower than G&A cost in the last two years (2014: $2.67 vs. $8.41 million; 2013: $1.89 vs. $9.31 million).) ^) I( t) n( ]3 b# w4 U

. N" N; Y7 Y/ r: h5 k) M, m2 f7 ~8 x. y3 {" U
I saw why four CAR-T therapies only cost RMB12 million when the Phase I results of CAR-CD19 came out on March 25, 2015. The trial enrolled nine adult patients with R/R B-cell ALL, only two had a complete response. One of those patients eventually died of graft-versus-host disease. The results were dim when compared to Juno Therapeutics’ (NASDAQ: JUNO) complete response rate of 90% presented at the ASH2014 Annual Meeting. only cost RMB12 million when the Phase I results of CAR-CD19 came out on March 25, 2015. The trial enrolled nine adult patients with R/R B-cell ALL, only two had a complete response. One of those patients eventually died of graft-versus-host disease. The results were dim when compared to Juno Therapeutics’ (NASDAQ: JUNO) complete response rate of 90% presented at the ASH2014 Annual Meeting.1 f+ a. g' K1 r- i1 |' r) {
$ K3 Y, q% o! ?. K1 _8 Z: i
+ {% F/ b0 T4 L! h  g
Here's still a biotech investment lesson: be careful of Chinese fraudsters in biotech clothing.
$ w4 ~0 `. D7 O& i. ^; b5 X7 d3 e

iytbxxg

Here's still a biotech investment lesson: be careful of Chinese fraudsters in biotech clothing., q4 u& C3 j+ o5 w! ]) m3 \+ c
好惭愧的语言呀* ]" Y& j  m3 I" {- J6 ^
这是哪个专家说的
" ], @$ K; R+ \/ y( w+ B2 J% `8 I

tim1403

这里要告诉你的是投资生物科技类股的教训：小心在中国那些披上生物科技外衣的骗子！$ K8 j' x/ ^/ D8 T" S& ]

sunnyhuan0629

我想请教下，那在中国，现在那些天使投资人怎么去评估项目？或者国内真的有很好的原创技术的话，会吸引到国外的投资者么？并且生命科学领域的投资热看起来才刚刚起步不久，应该还会持续，怎么理智地去行动呢？

tim1403

目前国外的基金还不能投资细胞治疗产业，因为他是限制外商投资的项目之一